Clinical Trial Update: DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating DEB-TACE combined with apatinib and a PD-1 antibody for intrahepatic cholangiocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization | Phase 2 | Status: COMPLETED